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ABSTRACT 
The uptake of [‘251]triiodothyroacetic acid ( [lzSI]Triac) in anterior 
pituitary cells was investigated and compared with that of [‘251]T3. 
Furthermore, the effects of Triac, T,, and Tq on TSH release were 
compared. Cells isolated from adult male Wistar rats were cultured for 
3 days in medium with 10% fetal calf serum. Uptake was measured at 
37 C with [‘251]Triac (100,000 cpm; 120 PM) or [“?]T3 (50,000 cpm; 50 
PM) in medium with 0.5% BSA. In this medium, the ratio of the free 
fractions of Triac, TB, and T1 was 1:8:1. Exposure of cells to 100 nM 
TRH for 2 h stimulated TSH release by 80-110% (P < 0.001). Com- 
paring total hormone levels (1 nM to 1 jtM), Triac and TS were equally 
effective in reducing this response, and both were lo-fold more effective 
than T,. The time-course (15 min to 4 h) of [“‘I]Triac uptake was 
similar to that of [?)Ta, showing equilibrium after 1 h. Unlabeled 
Triac (1 pM) reduced the uptake of [‘Z51]Triac and [lz51]T, at all time 
intervals. Expressed per pM free hormone, the cellular and nuclear 
uptake of [“‘I]Triac were twice those of [‘251]T3. The 15-min uptake of 
[‘2SI]Triac was reduced by incubation with 10 nM unlabeled Triac (35%; 
P c 0.001). Maximum inhibition (56%; P < 0.001) was found with 10 
PM Triac. A similar effect was seen with 10 PM T,, T,, or 3,3’,5,5’- 
tetraiodothyroacetic acid. Preincubation (30 min) and incubation (15 
min) with 10 SM oligomycin reduced the cellular ATP content by 51% 
(P c O.OOl), pI]T3-uptake by 77% (P < O.OOl), and [‘251]Triac iptake 
bv onlv 25% (P < 0.001). The temperature dependence of Vz511Triac 
ahd [lisI]T3 uptake was the same. Preincubation and incubation with 
10 FM monensin (reduces the Na+ gradient) or 10 pM monodansylca- 
daverine (inhibits receptor-mediated endocytosis) reduced 15-min [1251] 
Triac uptake by 15% (P < 0.005) and 19% (P c 0.005), respectively. 
The data show that 1) Triac, on the basis of the free hormone concen- 
tration, is more potent than Tz or T, in suppressing TSH secretion; 
and 2) the rapid uptake of [‘Z51]Triac by the anterior pituitary occurs 
by a carrier-mediated mechanism that is only partially dependent on 
ATP or the Na+ gradient. (Endocrinology 136: 2700-2707, 1994) 
T HE METABOLISM of T3 occurs by three pathways: deiodination, conjugation, and side-chain alteration. 
Whereas 50-60% of T3 in humans is deiodinated to 3,3’- 
diiodothyronine (l), alteration of the alanine side-chain, 
resulting in the production of 3,3’,5-triiodothyroacetic acid 
(Triac), may account for around 14% of T3 metabolism in 
man (2). However, under pathological conditions, as, for 
example, fasting, Triac production is substantially increased 
(3, 4). Furthermore, these researchers suggested that Triac 
might be of importance for the suppression of TSH secretion 
in fasting, which occurs despite low plasma TJ and T4 levels. 
Also, under conditions other than fasting, characterized by 
low plasma TSH, T3, and Tl, Triac might play a role in the 
suppression of TSH secretion (5). 
In euthyroid and hypothyroid subjects, administration of 
Triac suppresses basal TSH secretion (6-8) as well as the 
TSH response to TRH (6, 9). Furthermore, Triac is used in 
the treatment of patients with thyroid cancer (10, 11) and 
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generalized resistance to thyroid hormones (12, 13). How- 
ever, the question of whether the effects of Triac are specific 
for the pituitary gland has not been definitively answered 
(8, 9, 11, 14). 
Early in vitro studies showed that T3 and Triac were equally 
potent in the suppression of TSH production and displace- 
ment of [lz51]T3 from the nuclear binding sites in mouse 
thyrotropic tumor cells (15). In rat pituitary fragments super- 
fused with BSA-containing medium, both 0.1 PM Triac and 
0.1 PM TS reduced the TRH-induced TSH release by around 
25% (16). 
Previously, we reported evidence for carrier-mediated up- 
take of T3 and Tq in cultured anterior pituitary cells of 
euthyroid rats (17, 18). Moreover, T3 and T4 seem to share 
the same carrier in the pituitary (18, 19). The purpose of the 
present work was to study 1) the effect of Triac, compared 
to those of T3 and T4, on basal and TRH-induced TSH release; 
and 2) the mechanism of uptake of [‘251]Triac into cultured 
anterior pituitary cells. Furthermore, we questioned whether 
the uptake of [‘251]Triac occurred by the same transport 
mechanism as that described for T3 and Tq. 
Materials and Methods 
All solutions used for cell isolation and cell culture were obtained 
from Gibco Europe (Breda, The Netherlands), with the exception of 
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human serum albumin (Central Laboratory of the Red Cross Blood 
Transfusion Service, Amsterdam, The Netherlands), dispase (grade II; 
Boehringer, Mannheim, Germany), absorbed fetal calf serum (Flow 
Laboratories, Irvine, Scotland), and Fungizone (Bristol-Myers Squibb, 
Woerden, The Netherlands). Culture dishes (48 wells) were obtained 
from Costar (Cambridge, MA). All iodothyronines, 3,5diiodothyroacetic 
acid Triac, and 3,3’,5,5’-tetraiodothyroacetic acid (Tetrac), were ob- 
tamed from Henning Berlin (Berlin, Germany). Piperazine-NJ’-bis-[2- 
ethane sulfonic acid], HEPES, NJ-bis-[2-hydroxyethyl]2-aminoethane 
sulfonic acid, BSA (fraction V), monensin, oligomycin, and monodan- 
sylcadaverine (MDC) were purchased from Sigma Chemical Co. (St. 
Louis, MO). TRH was obtained from Hoechst (Frankfurt am Main, 
Germany). [3’-‘251]T3 (3070 pCi/pg) and carrier-free Nan51 were pur- 
chased from Amersham International (Aylesbury, United Kingdom). [3’- 
“‘I]Triac (2730 rCi/pg) was prepared from Na’251 and 3,5diiodothy- 
roacetic acid using the chloramine-T method (20). Sephadex LH-20 and 
G-25 were obtained from Pharmacia (Uppsala, Sweden). All other 
reagents were of the highest purity available. 
Animals 
AI1 experiments were performed using male Wistar rats, weighing 
220-250 g. The animals had free access to food and water and were 
kept in a controlled environment (21 C) with constant day length (12 
W 
Cell culture 
Animals (12-18 for each experiment) were killed between 0900-0930 
h by decapitation. The pituitary glands were removed within 5 min, the 
neurointermediate lobe was discarded, and the anterior lobes were 
collected in calcium- and magnesium-free Hanks’ Balanced Salt Solution 
supplemented with 10 g/liter human serum albumin, penicillin (lo5 U/ 
liter), Fungizone (0.5 mg/Iiter), and sodium bicarbonate (0.4 g/liter). 
Anterior pituitary cells were dissociated with dispase (final concentra- 
tion, 2.4 x IO3 U/liter), as described in detail previously (21). From each 
pituitary, around 1.5 X lo6 cells were obtained, and the viability of the 
cells, determined by trypan blue exclusion, was greater than 90%. 
The cells were cultured at 37 C in a water-jacketed incubator with 
5% COZ at a density of 5-8 X lo5 cells/well in 48-well culture dishes. 
The cells had attached to the wells after 2 days of culture. On day 3, 
the cells were used for experiments. The culture medium consisted of 
Minimum Essential Medium with Earle’s salts supplemented with non- 
essential amino acids, sodium pyruvate (1 mmol/liter), 10% fetal calf 
serum (in ex 
P 
eriments for Table 1, 10% absorbed fetal calf serum), 
penicillin (10 U/liter), Fungizone (0.5 mg/liter), L-glutamine (2 mmol/ 
liter), and sodium bicarbonate (2.2 g/liter), pH 7.4 (21, 22). 
Cellular uptake of r’“I]Triac and p”“IJT3 
Edinburgh, Scotland). The amount of [‘251]Triac or [i”I]T) taken up was 
expressed as a percentage of the added radioactivity (percentage of the 
dose). The same procedure was applied to incubations without cells 
(blanks). All results were corrected for the amount of radioactivity 
retained in the wells without cells. 
Nuclear binding of rz51]Triac and r’“I]T3 
After incubation, cells were washed once with ice-cold saline (0.9% 
NaCl). The cells were harvested from the wells with a rubber policeman 
in 1 ml PBS (on ice) and counted for 30 sec. Isotope uptake, calculated 
as a percentage of the dose with this method, gave similar values for 
the cellular radioactivity as the usual procedure with 0.1 N NaOH. All 
of the following procedures were performed on ice. A cell pellet was 
obtained after centrifugation (300 X g; 4 C; 7 mm), counted (30 set), 
and solubilized in 1 ml PBS containing 0.5% Triton X-100, as previously 
described (23). After 2 rnin of continuous vortexing, nuclei were spun 
down (900 x g; 4 C; 5 min) and washed once with 1 ml PBS containing 
0.5% Triton X-100. The nuclear pellets were counted for 5 min. 
LH-20 chromatography 
Aliquots of the incubation medium were chromatographed on Seph- 
adex LH-20 (24). Iodide was eluted from the column with 4 x 1 ml 0.1 
N HCI. Subsequently, possible conjugates were eluted eight times with 
1 ml HrO, and finally, the remaining Triac or T3 was eluted from the 
column four times with 1 ml 50% ethanol in 0.1 N NaOH. 
TSH release and cellular content 
After removal of the culture medium, cells were washed once with 
incubation medium. The culture medium was centrifuged (2000 x g), 
and the supematant was frozen until hormone determination. The 
incubation medium was identical to the culture medium, except that 
fetal calf serum was replaced by 0.5% BSA. The pituitary cells were 
preincubated for 2 h at 37 C in the absence or uresence of variable 
concentrations (1 nM to 1 PM) Triac, Ta, or Tr. The pieincubation medium 
was discarded, and fresh incubation medium was added which con- 
tained 100 nM TRH without or with the same concentrations Triac, Ts, 
or T, as those described above. Incubation was continued for 2 h at 37 
C. This medium was removed, centrifuged (2000 x g), and stored at 
-20 c. 
To determine the TSH content of cells, 0.5 ml incubation medium 
was added to the wells. The cells were scraped from the wells with a 
rubber policeman, and the wells were sonicated twice for 30 sec. The 
extracts were removed, and the wells were washed once with 0.5 ml 
medium. The two fractions were then combined (volume of cell extract, 
1.0 ml) and centrifuged (2000 X g) at room temperature, and the 
supematant was frozen until further analysis, 
After removal of the culture medium, cells were preincubated with 
0.5 ml incubation medium. The incubation medium was identical to the 
culture medium, except that the fetal calf serum was replaced by 0.1% 
or 0.5% BSA. Preincubation was carried out for 30 min at 37 C in the 
absence or presence of 10 PM oligomycine, MDC, or monensin. The 
medium was removed after preincubation, and incubation was started 
with 0.25 ml medium containing the same additions as those described 
above, 10 nM to 10 PM Triac, or 10 PM T,, TI, or Tetrac and in all cases 
[‘rsI]Triac (lOO,OOO-200,000 cpm; 120-240 PM) or [izsI]T3 (50,000 cpm; 
50 PM). 
TSH determination 
TSH was measured by RIA. TSH (2 pg) was labeled with ‘25I (1 mCi) 
by the lactoperoxidase method and subsequently purified on a Sephadex 
G-25 (medium) and a Sephadex G-100 column, as previously described 
(17). 
Free Triuc and T3 concentrations 
Calculation of the free Triac and free Tj concentrations was based on 
determination of the free fractions bv eauilibrium dialvsis (25). Deter- 
mination of the free Triac fraction was cbrrected for the fact that only 
between 55-65% of [‘?]Triac is precipitated with MgClr. 
In medium with 0.5% BSA, the free fractions of Triac, TS, and TI 
were 0.47 + 0.03% (n = 5), 3.45 + 0.05% (n = 4), and 0.41 f 0.03% 
(n = 5), respectively. In rat serum, the free fractions of Triac, T,, and TI 
were 0.028%, 0.381%, and 0.025%, respectively. The free Triac or TB 
fraction in 0.5% BSA did not change after the addition of 10 nM or 1 PM 
unlabeled Triac. 
Incubations lasting for more than 1 h were performed at 37 C in 
humidified air with 5% COZ. Incubations of shorter duration took place 
in a 37 C incubation chamber on a rotating device without COZ. 
Therefore, the NaHC03 in the culture medium was replaced by an 
equimolar amount of HEPES (8.9 mM), piperazine-NJ’-bis-[2-ethane 
sulfonic acid] (10.6 m) and NJ-bis-[2-hydroxyethyl]2-aminoethane 
sulfonic acid (11.2 mM). 
After incubation, the medium was removed, and the cells were 
washed with l-ml volumes of ice-cold saline to remove tracer not bound 
to the cells. Cells were dissolved in 1 ml 0.1 N NaOH and counted for 
‘? activity in a 16-channel y-counter (NE 1600, Nuclear Enterprises, 
In medium with 0.1% BSA, the free fraction of Triac was 1.84 f 
0.07% (n = 9). This value did not change after the addition of 10 nM 
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Triac (1.75 + 0.06%; n = 5), but it increased after the addition of 10 PM 
Triac, TS, Tq, or Tetrac to 2.55 + 0.07% (n = 5), 2.04 + 0.05% (n = 3), 
2.15 f 0.06% (n = 3), and 2.42% (n = 2), respectively. The free Triac 
fractions (in 0.1% BSA) in the presence of 10 PM MDC, oligomycin, or 
monensin were 1.77 f 0.07% (n = 5), 1.76 + 0.10% (n = 5), and 1.83 
+ 0.13% (n = 5), respectively. 
ATP determination 
The cellular ATP content was determined in perchloric acid (0.2 M) 
extracts with the Lumac A.E.C.-Kit (Lumac, Landgraaf, The Nether- 
lands). 
Statistics 
The statistical significance of the effects of the tested compounds on 
[‘251]Triac and [?]T3 uptake or on TSH secretion was evaluated by one- 
way analysis of variance and Student’s t test for unpaired observations. 
P < 0.05 was regarded as statistically significant. 
Results 
TSH release during culture 
To determine whether TX, Tq, or Triac affected basal TSH 
release from cultured anterior pituitary cells, these three 
hormones were added at a concentration of 10 nM to cells 
cultured in medium supplemented with absorbed fetal calf 
serum. In addition, the effects of rT3 (10 nM) and TRH (1 nM) 
were tested (Table 1). The inhibitory effect of the thyroid 
hormones or analogs on basal TSH secretion during 3 days 
of culture decreased in the order Triac > T3 > T4 > rT3. The 
presence of 1 nM TRH almost doubled TSH release. In two 
separate experiments, it was found that total TSH (released 
into the medium plus cellular content) increased by 65% 
(P < 0.001) after culture in the presence of 1 nM TRH 
(not shown). 
TSH release during short term exposure to TRH 
The effects of Triac, Ts, and T4 were also compared with 
respect to inhibition of TRH-induced TSH release during 
TABLE 1. Effects of Triac, iodothyronines, and TRH on TSH 
release during culture of anterior pituitary cells 
EXP 
Conditions 
TSH release (ng): 
addition present during 
3 days of culture Last day of culture 
Controls 37.2 f 0.8 (9) 30.6 + 0.4 (8) 
10 nM T, 31.1 + 0.5 (6)” 26.6 + 0.1 (3)* 
10 nM T, 34.0 + 0.5 (3) 28.8 + 0.8 (3) 
10 nM Triac 28.7 + 1.2 (3)” 27.4 f 1.6 (3)’ 
10 nM rT, 35.6 f 1.7 (3) 32.6 + 1.0 (3) 
1 nM TRH 71.7 + 3.7 (3)” ND 
Data represent the mean + SE of three to nine observations in two 
independent experiments. Anterior pituitary cells (500,000 cells/well) 
were cultured for 3 days in culture medium containing 10% absorbed 
fetal calf serum. Hormones were added either at the start of culture 
(first column) or after 2 days of culture (last column) at the indicated 
concentrations. TSH in the culture medium was measured by RIA. 
ND, Not determined. 
a P C 0.001 VS. controls. 
b P < 0.005. 
c P < 0.01. 
short (2-h) incubation experiments. As shown in Table 2, 
TSH release increased by around 80% after exposure to 100 
nM TRH. At the same time, the cellular TSH content de- 
creased proportionally, suggesting that TRH stimulated the 
release of stored TSH (not shown). The stimulating effect of 
TRH on TSH release was almost completely blocked by 
preincubation and incubation with 10 nM or 1 PM T3 or Triac 
(Table 2). 
In two experiments, we compared the effects of Triac and 
T4 at a concentration of 25 nM on TRH-induced TSH release. 
TSH release (4.20 + 0.37 ng; n = 9) was stimulated 2-fold 
after exposure to 100 nM TRH (8.73 + 0.25 ng; n = 9; +108%; 
P < 0.001). After preincubation for 2 h with 25 nM Triac or 
T4, TSH release was 4.92 + 0.25 ng (n = 6) and 5.96 + 0.49 
ng (n = 6), respectively (0.05 < P < 0.10). 
Finally, we tested within one experiment the effects of 
Triac, T3, and T4 on TRH-induced TSH release at lower 
concentrations than those of the previous series. The results 
shown in Table 3 demonstrate that at concentrations of 1, 
2.5, and 10 nM, T3 and Triac were equally potent in suppres- 
sion of the TRH-induced TSH release. Tl, however, had no 
significant inhibitory effect at a concentration of 2.5 nM. The 
effect of T4 increased with higher concentrations, and the 
effect of 100 nM T, was approximately as large as that of 10 
nM T3 or Triac. 
Time course of [‘251]Triac and [lz51]T3 uptake 
Figure 1 shows the time course of uptake of [‘251]Triac 
(Fig. 1A) compared with that of [lz51]T3 (Fig. 1B) in cultured 
anterior pituitary cells. The uptake of the two isotopes was 
also measured in the presence of 1 PM unlabeled Triac (open 
symbols in Fig. 1, A and B). The uptake of [lz51]Triac and [125I] 
T3 showed a steep phase up to 1 h of incubation. Between 1 
and 4 h of incubation, the uptake of [1251]T3 showed some 
further increase, whereas that of [‘251]Triac had reached the 
maximum level. 
The presence of 1 PM unlabeled Triac significantly reduced 
the uptake of both [‘251]Triac and [‘251]T3 at any time point, 
TABLE 2. Short term effects of T, and Triac on TRH-induced 
TSH release from cultured anterior pituitary cells 
Exp Conditions TSH Release (ng) 
Stimulation p 
6) 
Controls (n = 12) 
+ TRH (100 nM) (n = 12) 
TRH + 10 nM T, (n = 5) 
TRH + 1 T1 (n pM = 6) 
TRH + 10 nM Triac (n = 9) 
TRH + 100 nM Triac (n = 9) 
TRH + 1 Triac pM (n = 9) 
3.37 + 0.07 
6.07 + 0.05 +80 <O.OOl” 
3.87 + 0.15 +15 <0.001* 
3.05 + 0.09 -9 <o.oolb 
3.42 + 0.06 +1 <O.OOlb 
3.43 * 0.10 +2 <O.OO1b 
3.01 + 0.04 -11 <0.001* 
Data indicate the mean f SE of 5-12 observations from 3 independ- 
ent experiments. Anterior pituitary cells were cultured for 3 days at a 
density of 500,000 cells/well. The cells were preincubated for 2 h in the 
absence or presence of T, or Triac at concentrations of 10 nM to 1 pM. 
Then, they were incubated with TRH (100 nM) for 2 h without or with 
the additions indicated. TSH was measured in the incubation medium 
by RIA. 
a Vs. controls. 
* Vs. TRH alone. 
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TABLE 3. Comparison of the short term effects of Triac, T,, and 
T, on the TRH-induced TSH release from cultured anterior pituitary 
cells 
Exp Conditions 
TSH release Stimulation 
(nd (%) 
P 
Controls (6) 
+ 100 nM TRH (6) 
TRH + 1 nM Tg (3) 
TRH + 2.5 nM Tg (3) 
TRH + 10 nM T3 (3) 
TRH + 1 nM Triac (3) 
TRH + 2.5 nM Triac (3) 
TRH + 10 nM Triac (3) 
TRH + 100 nM Triac (3) 
TRH + 2.5 nM T, (3) 
TRH + 10 nM T, (3) 
TRH + 100 nM T, (3) 
TRH + 1 /.tM T, (3) 
3.97 + 0.35 
7.24 + 0.22 +82 
5.64 f 0.25 +42 
5.65 f 0.43 +42 
5.50 f 0.13 +39 
5.73 * 0.15 +44 
5.79 + 0.26 +46 
5.47 + 0.15 +38 
4.96 f 0.12 +25 
6.70 + 0.30 +69 
6.44 + 0.09 +62 
5.32 + 0.32 +34 
4.37 + 0.47 +10 
<0.001” 
<0.001* 
<O.OOlb 
<0.001* 
<0.001* 
<0.001* 
<O.OOlb 
<0.001*~’ 
NSb 
<0.05*nd 
<O.OOlb 
<0.001* 
Data show the mean + SE of three to six observations in a single 
experiment. Anterior pituitary cells were cultured for 3 days at a density 
of 500,000 cells/well. The experiment was performed exactly as de- 
scribed in Table 2. 
a Vs. controls. 
* Vs. TRH alone. 
‘P < 0.05 or less us. TRH plus 1 or 2.5 nM Triac. 
‘I’ < 0.05 or less us. TRH plus 10 nM Triac or 10 nM T,. 
and the effect was largest after 4 h [89% for [iz51]Triac (P < 
0.001; n = 6) and 63% for [1251]T3 (P < 0.001; n = 6)]. It is 
evident from the upper curves in Fig. 1, A and B, that the 
uptake, expressed as a percentage of the dose of [1251]T3, was 
3-fold higher than that of [‘251]Triac. One important factor 
that explains this difference is the different free fraction of 
the two isotopes in buffer with 0.5% BSA, i.e. 0.47% for [1251] 
Triac and 3.45% for [1251]T3. By expressing the uptake data 
per PM free hormone, the curves presented in Fig. 1C were 
obtained, which clearly shows that the uptake of [‘251]Triac 
was actually more than twice that of [1251]T3. 
The media from the 4-h incubations were chromato- 
graphed on LH-20 columns to determine whether [1251]T3 or 
[1251]Triac was metabolized by the pituitary cells. In the media 
of incubations with [1251]T3 (n = 3), 99.9 f 3.5% of the 
radioactivity was recovered in the iodothyronine fraction. In 
the media of incubations with [1251]Triac (n = 3), 100.5 f 
2.1% (n = 3) was recovered in the iodothyronine fraction 
(not shown). 
The effect of 10 nM unlabeled Triac on the uptake of [125I] 
Triac and [1251]TJ was tested in incubations lasting 1 h. Again, 
it can be seen in Fig. 2 that the uptake of [‘251]Triac (n = 6) 
was 3-fold greater than that of [1251]T3 (n = 6; P < 0.001). 
The presence of 10 nM unlabeled Triac, which did not change 
the free fraction of [1251]Triac or that of [1251]T3, reduced the 
uptake of [‘251]Triac by 67% (P < O.OOl), but reduced that of 
[1251]T3 by only 35% (P < 0.001). 
Nuclear binding of [‘2sI]Triuc and [‘““IJT, 
To assess nuclear binding of T3 and Triac, anterior pituitary 
cells (800,000 cells/well) were incubated for 1 h with [1251] 
Triac or [1251]T3 in the absence or presence of 10 PM unlabeled 
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FIG. 1. Time course of uptake of [iz61]Triac (A) and [Y]T3 (B) in 
cultured anterior pituitary cells in the absence (A and 0) or presence 
(A and 0) of 1 pM unlabeled Triac. In C, the uptake of [?]Triac and 
[‘261]T3 is expressed per pM free hormone. Cells were cultured for 3 
days at a density of 500,000 cells/well. After removal of the culture 
medium, they were preincubated for 30 min in incubation medium with 
0.5% BSA. Thereafter, they were incubated in the same medium for 
periods of 15 min, 1 h, or 4 h with [“‘I]Triac (100,000 cpm) or [‘261]T3 
(50,000 cpm) without or with unlabeled Triac, as described in Materials 
and Methods. Data represent the mean f SE of six observations from 
two independent experiments. 
Triac or TS. To increase the free Triac fraction and, thus, the 
availability of isotope to the cells, [1251]Triac uptake was 
measured in buffer with 0.1% BSA in this experiment. As 
shown in the first column of Table 4, the total uptake (per- 
centage of the dose) of [1251]Triac and [1251]T3 under these 
different incubation conditions was approximately the same. 
Again, the presence of unlabeled Triac showed a greater 
inhibitory effect on the cellular uptake of [1251]Triac than on 
that of [1251]T3. Also, the inhibitory effect of unlabeled T3 was 
greater on cellular [1251]Triac uptake than on [1251]T3 uptake 
(Table 4, second column). The nuclear pellet (Table 4, third 
column) contained roughly the same amounts of [1251]Triac 
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FIG. 2. Uptake of [‘*‘I]Triac and [iz51]T3 by cultured anterior pituitary 
cells in the absence or presence of 10 nM unlabeled Triac. Cells were 
cultured for 3 days at a density of 500,000 cells/well. Preincubation (30 
min) and incubation (60 min) were performed as described in Fig. 1, 
except that half of the incubations contained 10 nM unlabeled Triac. 
Bars represent the mean f  SE of six observations from two independent 
experiments. *, P < 0.001, 10 nM Triac us. no additions. 
TABLE 4. Total and nuclear binding of [“‘I]Triac and [“‘I]T3 in 
cultured anterior pituitary cells 
Exp Conditions 
[‘“I]Radioactivity (% dose) 
Total uptake Cell pellet Nuclear pellet 
[‘*51]Triac 
+lO Triac pM 
+lO T, Irk 
4.87 2.67 0.84 
1.41 0.52 0.02 
1.32 0.50 0.02 
[ ‘=I]T3 4.40 2.31 0.70 
+lO Triac PM 3.07 1.17 0.03 
+I0 /AM Ts 2.39 0.96 0.05 
Data show the means of triplicate observations in a single experi- 
ment. Anterior pituitary cells were cultured for 3 days at a density of 
800,000 cells/well. Preincubation (30 min) and incubation (1 h) for 
determination of [iz51]Triac uptake (200,000 cpm) were carried out in 
medium with 0.1% BSA, and for determination of [“‘I]T, uptake 
(100,000 cpm) in medium with 0.5% BSA. Unlabeled Triac or T, (10 
PM) was only present during incubation. Total uptake was measured 
in cells scraped from the wells in 1 ml PBS. After centrifugation of the 
suspension, a cell pellet was obtained and counted. The nuclear pellet 
was obtained after treatment with Triton X-100 (for further details, 
see Materials and Methods). 
and [lz51]T3 after 1 h (31% and 30% of the radioactivity in 
the cell pellets, respectively), and the nuclear binding of [1251] 
Triac or [lz51]T3 was almost completely blocked by simulta- 
neous incubation with unlabeled Triac or T3. Relative to the 
free fraction in the incubation medium, the nuclear uptake 
of [1251]Triac was about twice that of [1251]T3 (0.84% dose with 
a free fraction of 1.84% for [‘251]Triac and 0.70% dose with 
a free fraction of 3.45% for [1251]T3). 
Plasma membrane uptake of [‘251]Triac 
To evaluate the uptake of [‘251]Triac at the level of the 
pituitary plasma membrane, experiments were performed in 
a manner similar to that previously described for [1251]T3 and 
[1251]T4 with 15 min of incubation (17, 18). With 0.5% BSA 
in the medium, the 15-min uptake of [1251]Triac amounted to 
0.46 f 0.04% dose (n = 8), and with 0.1% BSA in the 
medium, it was 1.70 f 0.06% dose (n = 8) (P < 0.001). 
Corrected for the free hormone concentration, the 15min 
[1251]Triac uptake in 0.5% BSA was 0.245 + 0.021 fmol/pM 
free Triac (n = 8), and that in 0.1% BSA was 0.231 f 0.008 
fmol/pM free Triac (n = 8; P = NS). Therefore, the 15-min 
uptake experiments were performed in medium with 0.1% 
BSA. 
Figures 3 and 4 show the results of four experiments, in 
which the competitive effects of various concentrations of 
unlabeled Triac, TJ, T4, or Tetrac were tested. The presence 
of 10 nM Triac resulted in significantly lower uptake of [1251] 
Triac (35%; P < O.OOl), whereas 10 PM Triac produced a 
maximal inhibitory effect of 56% (P < 0.001; Fig. 3). A 
similar inhibitory effect on [‘251]Triac uptake was obtained in 
the presence of 10 PM TJ, T4, or Tetrac (Fig. 4). When [1251]T3 
uptake was measured in the presence of 10 PM TJ, T4, Triac, 
or Tetrac, uptake was reduced by 70%, 60%, 47%, and 48%, 
0 10 100 1,000 10,000 
unlabeled Triac added (nM) 
FIG. 3. Effects of increasing concentrations unlabeled Triac on the 15 
min uptake of [iz61]Triac in cultured anterior pituitary cells. Cells were 
cultured for 3 days at a density of 500,000 cells/well. After removal of 
the culture medium, they were preincubated for 30 min in medium 
containing 0.1% BSA. This was followed by incubation for 15 min in 
the same medium, with [iz51]Triac (100,000 cpm) and unlabeled Triac 
added at concentrations of 10 nM to 10 pM. Bars represent the mean f  
SE of six to eight observations from two independent experiments. *, P 
< 0.001 vs. no additions. 
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FIG. 4. Effects of Triac, TS, T,, and Tetrac on the 15-min uptake of 
[‘?]Triac in cultured anterior pituitary cells. Cells were cultured for 3 
days at a density of 500,000 cells/well. Experiments were performed as 
described in Fig. 3, without or with 10 PM Triac, Ta, T,, or Tetrac 
present during the incubation. Bars represent the mean f  SE of six to 
nine observations from three independent experiments. *, P < 0.001 
vs. no additions. 
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respectively (all P < 0.001). 
Preincubation and incubation with MDC, oligomycin, and 
monensin, can be used to study the possible involvement of 
receptor-mediated endocytosis, energy dependence, and the 
dependence of the uptake process on the Na+ gradient, 
respectively (17, 18). When tested at a concentration of 10 
PM, MDC reduced the 15-min uptake of [1251]Triac by 19% 
(n = 11; P < 0.005), oligomycin reduced it by 23% (n = 11; 
P < O.OOl), and monensin reduced it by 15% (n = 11; P < 
0.005; Fig. 5). 
Finally, the 15-min uptake of [‘251]Triac was directly com- 
pared with that of [lz51]T 3 with respect to the energy depend- 
ence and temperature dependence of the uptake process. 
Under control conditions, the uptake of [1251]T3 amounted to 
1.55 + 0.05% dose (n = 9), and that of [“‘I]Triac was 1.50 f 
0.05% dose (n = 11; Fig. 6, first and third columns). Expressed 
per PM free hormone, the uptake of [1251]T3 was 0.112 rtr 
0.004 (n = 9), and that of [‘251]Triac was 0.204 + 0.006 fmol 
(n = 11; P < 0.001). Preincubation and incubation with 10 
PM oligomycin reduced the cellular ATP content by 51% (P 
< 0.001; Fig. 6, last two columns). At the same time, the 
uptake of [1251]T3 was reduced by 77% (P < O.OOl), and that 
of [‘251]Triac by 25% (P < 0.001). On the other hand, the 
temperature dependences of the two uptake processes were 
comparable. At 0 C, uptake of [‘251]Triac was 0.19 + 0.04% 
dose (n = 6), and that of [1251]T3 was 0.11 + 0.03% dose (n 
= 6). Both increased 5-fold when the temperature was in- 
creased to 22 C: [1251]Triac uptake, 0.89 + 0.02% dose (n = 
6); [*251]T3 uptake, 0.80 + 0.04% dose (n = 6). When the 
temperature was raised from 22 to 37 C, the uptake of the 
two isotopes increased 2-fold: [‘251]Triac uptake, 1.76 + 
0.06% dose (n = 6); [1251]T3 uptake, 1.71 + 0.04% dose (n = 
6). 
Discussion 
The results of the present study demonstrate that [1251] 
Triac is rapidly taken up by the pituitary. At comparable free 
medium concentrations (Triac, 0.6-2.2 PM; T3, 1.7 PM), both 
cellular and nuclear uptakes of [1251]Triac were at least twice 
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FIG. 5. Effects of MDC, oligomycin, and monensin on the 15-min 
uptake of [‘261]Triac in cultured anterior pituitary cells. Cells were 
cultured for 3 davs at a densitv of 500.000 cells/well. Preincubation (30 
min) and incubation (15 min”) were performed as described in Fig. 3, 
except that MDC, oligomycin, and monensin (10 PM) were present 
during preincubation and incubation. Bars represent the mean + SE of 
11 observations from 4 independent experiments. *, P < 0.001; **, P < 
0.005 (us. no additions). 
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FIG. 6. Effects of oligomycin on the 15-min uptake of [“‘I]T3 and [‘““I] 
Triac and on ATP contents of cultured anterior pituitary cells. Anterior 
pituitary cells were cultured for 3 days at a density of 500,000 cells/ 
well. Cells were preincubated for 30 min without or with 10 pM 
oligomycin. Uptake experiments were performed for 15 min with [‘““I] 
T1 (50,000 cpm/well in medium with 0.5% BSA) or [iz51]Triac (100,000 
cpm/well in medium with 0.1% BSA) without or with 10 pM oligomycin 
present. Cells used for determination of ATP content were preincu- 
bated and incubated without or with 10 pM oligomycin, but without 
tracer. Bars show the mean f SE of 9-14 observations from 6 experi- 
ments. *. P < 0.001 vs. controls. 
those of [1251]T3. Furthermore, Triac was, on the basis of the 
free hormone concentration, more effective than T3 or Tq in 
suppression of basal and TRH-induced TSH release. 
These comparisons were made in anterior pituitary cells in 
vitro, i.e. an experimental system in which differences in the 
MCR do not play a role, and neither [‘251]Triac nor [1251]T3 
was metabolized. On the other hand, the cells showed met- 
abolic activity, because they were previously shown to deiod- 
inate around 20% of cellular [1251]Tq to [1251]T3 in 24 h (18). 
In the 2-h incubation experiments with TRH, Triac was, 
on the basis of the total hormone concentration, equally 
potent as TJ in suppression of the TRH-induced TSH release. 
To obtain a similar effect with Tq, at least a lo-fold higher 
total dose was required compared to Triac or TJ. However, 
when the difference in the free fractions of Triac, TS, and T4 
is taken into account (ratio of the free fractions, 1:8:1), the 
order of potency for inhibition of TRH-induced TSH release 
appears to be Triac > T3 > Tq, A significant reduction of the 
TSH response to TRH was seen with concentrations as low 
as 1 nM Triac or TJ. The anterior pituitary cell preparation 
may be more sensitive to demonstrate these effects than 
superfused pituitary fragments (16). In the latter system, 100 
nM Triac or T3 (in medium with 0.25% BSA) was required to 
significantly reduce the TSH response to TRH. 
It has been demonstrated in viva that T3 or T, injected into 
hypothyroid rats reduced the plasma TSH level within 2 h 
(26). This effect was related to nuclear binding of TJ (26) and 
probably reflects interference with the TSH release process. 
On the other hand, when pituitary cells were exposed for a 
prolonged period of time (1-3 days during culture) to Triac, 
TB, Tq, or TRH, the results were more likely to reflecthinter- 
ference with TSH synthesis. This idea was supported by the 
finding that the total TSH (medium plus cells) was signifi- 
cantly increased after culture in the presence of 1 nM TRH, 
suggesting de nova TSH synthesis, which confirmed the early 
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results of Vale et al. (27). 
Triac seemed to be the most effective in suppression of 
TSH release during culture. Addition of the same total con- 
centration of T4 (10 nM) showed a smaller effect on TSH 
release than that obtained with T3 or Triac after both 1 and 
3 days of culture. When it is taken into account that in 
medium with 10% serum, the free Triac fraction is much 
lower than that of TJ, Triac is the most effective in inhibition 
of TSH synthesis. This was also observed in thyrotropic 
tumor cells cultured in the presence of serum, when thyroid 
hormones or analogs were added for 24 h (15). In that study, 
T3 and Triac were equally potent when total hormone con- 
centrations were compared, and both showed a IO-fold 
higher potency than T4. 
Both cellular and nuclear uptakes per PM free hormone of 
[‘251]Triac were twice those of [1251]T3. Studies with nuclei 
isolated from thyrotropic tumor cells, pituitary tumor cells, 
normal rat liver, or heart demonstrated an equal or even 
higher potency of Triac compared to TJ to displace nuclear 
[1251]T3 binding (15, 28-30), indicating a high affinity for 
Triac of the thyroid hormone receptor. 
The initial rate of [1251]Triac uptake per PM free hormone 
measured over 15 min was twice that of [1251]T3. The latter 
was previously shown to be as high as that of [lz51]T4 (18). 
The 15-n-tin [‘251]Triac uptake was reduced by simultaneous 
incubation with unlabeled Triac at concentrations as low as 
10 nM, suggesting the existence of a carrier in the pituitary 
cell membrane. Apparently, this carrier also recognized T3, 
T4, and Tetrac, as each of these substances reduced [‘251]Triac 
uptake to the same extent as Triac when added at a concen- 
tration of 10 pcM. 
The experiments with oligomycin showed that the uptake 
of [1251]Triac was only partially dependent on the cellular 
energy status; the effect of oligomycin on the uptake of [125I] 
Triac was only 50% of that on the uptake of [1251]T3. Fur- 
thermore, the experiments with monensin indicate that the 
uptake process was not strictly dependent on the Na+ gra- 
dient. Compared with our previous observations on the effect 
of monensin on the uptake of [lz51]T3 or [1251]T4 (-40%) (17, 
18), the effect on the uptake of [‘251]Triac was much smaller. 
The same conclusion holds for the effect of MDC. Part of 
this difference might be due to the fact that the data were 
not corrected for nonspecific uptake of [‘251]Triac or [1251]T3, 
and that the nonspecific uptake of [‘251]Triac might have been 
larger than that of [1251]T3. On the other hand, the tempera- 
ture dependence of the uptake of [1251]Triac and [1251]T3 was 
the same. 
Together, our results suggest that [‘251]Triac is taken up by 
pituitary cells by a carrier-mediated mechanism that is influ- 
enced to only a minor extent by the cellular energy status or 
the Na+ gradient. [‘251]Triac uptake, expressed per PM free 
hormone was twice as high as that of [*251]T3. Nevertheless, 
the uptake mechanism for Triac shared some properties with 
the transport of TS (and T4). This could mean that Triac is 
partly taken up by the anterior pituitary by the same trans- 
port mechanism as that for T3 and T4 and partly by another 
transport system. 
When Triac is used to suppress TSH secretion in patients, 
it has to be administered in relatively large doses (9-l 1) due 
to its short half-life (-6 h) (7). This idea is supported by the 
observation that dividing the daily Triac dose into four parts 
had a more pronounced effect on serum TSH in euthyroid 
subjects than a single dose (8). One of the factors that could 
explain the short half-life of Triac in humans is the recent 
finding that Triac is extremely rapidly glucuronidated in the 
liver (31). 
It was recently suggested that Triac might be of importance 
in the euthyroid sick syndrome (3-5). This syndrome is 
characterized by low serum TJ and T4 levels without a rise 
in serum TSH (32). The normal serum level of Triac is about 
50 PM (2) compared to a normal serum T3 level of 2000 PM 
(26). As the free fraction of Triac in serum is much lower 
than that of T3 (33), the difference in free hormone concen- 
tration in normal subjects may be a factor of 400. During the 
euthyroid sick syndrome, the serum T3 level may drop as 
much as 50%, with a concomitant decrease in the free TJ 
concentration (32). In contrast to TS, Triac is strongly bound 
to prealbumin in serum, and the prealbumin level decreases 
substantially during illness (5), leading to a rise in the free 
Triac fraction (3- to 9-fold) (Everts, M. E., and T. J. Visser, 
unpublished). This effect should be added to an increased 
Triac production, whereas deiodination of T4 to TJ is dimin- 
ished (3, 4). Together with our observations that the thyro- 
troph seems to be more sensitive to Triac than to TJ and the 
fact that the uptake of Triac is higher than that of TJ, it is 
possible that Triac plays a role in the control of TSH secretion 
in the euthyroid sick syndrome. 
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